HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Gout With Hyperuricemia in Adults
Conditions
Primary Gout With Hyperuricemia in Adults
Trial Timeline
Apr 30, 2022 → Jul 31, 2022
NCT ID
NCT05347498About HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Primary Gout With Hyperuricemia in Adults. The current trial status is unknown. This product is registered under clinical trial identifier NCT05347498. Target conditions include Primary Gout With Hyperuricemia in Adults.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06414837 | Phase 3 | Recruiting |
| NCT06139393 | Phase 3 | Completed |
| NCT05347498 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Primary Gout With Hyperuricemia in Adults